TG Therapeutics | TGTX - Ordinary Share Capital


TG Therapeutics reported $155.31M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Alaunos Therapeutics USD 2.38M 172K Mar/2026
Amgen USD 540M 1000K Mar/2026
Ardelyx USD 244.35M 1.38M Dec/2025
Arrowhead Research USD 137.39M 1.69M Dec/2025
Bayer EUR 982.42M 0 Dec/2025
Biogen USD 146.7M 200K Sep/2025
Corcept Therapeutics USD 107.33M 1.36M Mar/2026
Curis USD 12.93M 12.87M Dec/2025
Gilead Sciences USD 1.24B 1000K Mar/2026
Infinity Pharmaceuticals USD 90K 1000 Jun/2023
J&J USD 2.41B 1.74M Dec/2025
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
Novartis USD 1.91B 60K Mar/2026
Novavax USD 162.58M 106K Dec/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
TG Therapeutics USD 155.31M 95K Dec/2025
Verastem USD 77.74M 77.74M Dec/2025
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026